Goldman Sachs
LJPC

Goldman Sachs’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Goldman Sachs’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-60,000
Closed -$1.93M – 6746
2017
Q4 		$1.93M Buy
+60,000
New +$1.96M ﹤0.01% 3833
2017
Q3 		– Sell
-36,000
Closed -$1.07M – 7184
2017
Q2 		$1.07M Buy
+36,000
New +$1.03M ﹤0.01% 4390

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KT
Kevin Tang $783 AUM 75.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs's LJPC Position: Q2 2022 in Review

Goldman Sachs sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2022, closing a stake of 13,718 shares — an estimated $59K sold.

Goldman Sachs first reported a position in LJPC in Q1 2015 and held it in 25 quarters. The position peaked at $1.16M in Q3 2018. 41 funds tracked by Wall St. Rank hold LJPC as of Q2 2022.

  • Goldman Sachs reported no remaining La Jolla Pharmaceutical Company position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 13,718 La Jolla Pharmaceutical Company shares in Q2 2022, an estimated $59K.
  • Goldman Sachs first reported a position in La Jolla Pharmaceutical Company in Q1 2015 and held it in 25 quarters.
  • Goldman Sachs's La Jolla Pharmaceutical Company position peaked at $1.16M in Q3 2018.
  • 41 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.